🔎 Trials Near Me

Inicio › Mieloma múltiple › Texas › Dallas

Ensayos clínicos de Mieloma múltiple en Dallas, TX

17 estudios para Mieloma múltiple buscan participantes en centros de Dallas y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.

Texto oficial del estudio (inglés)

¿Reclutando participantes para un estudio? Destácalo en la parte superior de esta página — $99 por 30 días →

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

ReclutandoFase 3
  • Baylor University Medical Center, Dallas
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07518186

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

ReclutandoFase 3
  • Baylor University Medical Center, Dallas
  • UT Southwestern Medical Center, Dallas
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07258511

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

ReclutandoFase 3
  • University of Texas Southwestern Medical Center, Dallas
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT05552222

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

ReclutandoFase 2
  • UT Southwestern Medical Center, Dallas
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06297226

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

ReclutandoFase 1/2
  • University of Texas - Southwestern Medical Center /ID# 271914, Dallas
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06953960

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

ReclutandoFase 3
  • Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas
  • Baylor University Medical Center, Dallas
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 ago 2026 · NCT06152575

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

ReclutandoFase 1
  • University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT05651932

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

ReclutandoFase 1/2
  • Research Site, Dallas
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT05850234

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

ReclutandoFase 3
  • Research Site, Dallas
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 ago 2026 · NCT07764978

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

ReclutandoFase 1
  • Baylor University Medical Center, Dallas
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 ago 2026 · NCT07280013

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

ReclutandoFase 1/2
  • University of Texas - Southwestern Medical Center /ID# 274360, Dallas
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 jul 2026 · NCT06892522

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

ReclutandoFase 1
  • Texas Oncology - Dallas - Worth Street /ID# 280064, Dallas
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 jul 2026 · NCT05650632

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

ReclutandoFase 1
  • University of Texas Southwestern, Dallas
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 jul 2026 · NCT05137054

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

ReclutandoFase 2
  • University of Texas Southwestern, Dallas
Edades de 19 en adelante · Todos los sexos · Actualizado el 4 jun 2026 · NCT06974786

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

ReclutandoEstudio observacional
  • Ut Southwestern, Dallas
Todas las edades · Todos los sexos · Actualizado el 22 ene 2026 · NCT06357754

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

ReclutandoFase 1
  • University of Texas Southwestern Medical Center, Dallas
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2025 · NCT05722418

Más información sobre Mieloma múltiple en MedlinePlus

Ensayos de Mieloma múltiple en otras ciudades

Otros estudios en Dallas

De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.